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Background. Heparins are currently the anticoagulants of
choice in long-term hemodialysis (HD). Because of their short-
comings, including the increasing incidence of heparin-induced
thrombocytopenia (HIT II), alternative anticoagulation is nec-
essary. The study objectives were to provide safe and effective
HD by investigating an appropriate PEG (polyethylene glycol)-
Hirudin dosage regimen in patients on HD, as well as to compare
the safety, tolerability, and efficacy of PEG-Hirudin with that
of unfractionated heparin (UFH).
Methods. Twenty patients (12 males, 8 females, mean age
57.8 years) with end-stage renal disease (ESRD) took part in the
study. Dialysis sessions lasting a mean of 4.3 hours (QB 250 to
300 mL/min, QD 500 mL/min) were performed 3 times a week
with a Gambro GFS plus 16 dialyzer. Ten patients (group I)
received UFH at 3 regular dialysis sessions (HD1−3) followed
by 5 dialysis sessions using PEG-Hirudin (HD4−8). Another 10
patients (group II) received UFH at 3 regular dialysis sessions
(HD1−3) followed by 10 sessions on PEG-Hirudin (HD4−13).
The starting dose of PEG-Hirudin was a single bolus injection
of 80 lg/kg BW (HD4), except for the first patient, who received
50 lg/kg BW followed by a 12 lg/kg bolus. Before each of the
following sessions (HD5−13), an individualized PEG-Hirudin
dose of between 26 to 65 lg/kg body weight (BW) (mean dose
41 lg/kg BW) was injected. PEG-Hirudin plasma and blood
concentrations derived from anti-Iia activity and ecarin clotting
time (ECT), respectively, activated partial thromboplastin time
(aPTT), bleeding time, and arteriovenous (AV) fistula compres-
sion time were investigated to calculate the pharmacokinetic
parameters or to assess anticoagulant efficacy.
Results. Mean predialysis PEG-Hirudin plasma concentra-
tions increased up to a maximum of 488 ng/mL in group I (HD8)
and up to 536 ng/mL in group II (HD8). Mean plasma concen-
trations measured at 5 minutes after the 1st (HD4), 5th (HD8),
and 10th (HD13) PEG-Hirudin injection ranged from 1076 to
1298 ng/mL. Mean post-dialysis plasma levels ranged from 818
to 995 ng/mL. Mean predialysis aPTT was not affected by UFH,
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but was prolonged by 46 to 56 seconds by PEG-Hirudin. Five
minutes after injecting PEG-Hirudin or UFH, mean aPTT was
prolonged to a maximum of 85 and 188 seconds, respectively.
Mean post-dialysis aPTT values ranged from 60 to 68 seconds af-
ter PEG-Hirudin and 34 to 46 seconds after UFH. PEG-Hirudin
was well tolerated; no serious adverse events or bleeding com-
plications were observed. Safety assessments yielded no signif-
icant difference between the two anticoagulants.
Conclusion. This pilot study confirmed the usefulness and
tolerability of a PEG-Hirudin dose regimen consisting of a sin-
gle, fixed bolus dose of 80 lg/kg BW injected before starting the
first dialysis session (HD4) and followed by a dose titration pe-
riod over at least 4 sessions (HD5−8), which again was followed
by a fixed maintenance dose period (HD9−13). On the basis of
PEG-Hirudin data from patients with various degrees of re-
nal insufficiency but not undergoing hemodialysis and prior
recombinant-hirudin (r-hirudin) experience, patients were
titrated into an EC-controlled dose range that proved to be ef-
ficacious enough to prevent clotting and safe enough to prevent
bleeding. Due to the favorable pharmacokinetic properties of
PEG-Hirudin, a residual anticoagulant effect is maintained in
the intervals between dialysis sessions, and this permanent state
of anticoagulation may prevent vascular access complications
as well as other vascular events.
Heparins are currently the anticoagulants of choice in
long-term hemodialysis (HD) treatment [1, 2]. However,
these agents have several shortcomings. They require an-
tithrombin III (AT III) as a cofactor, they are not effec-
tive against thrombin that is already bound to the fibrin
clot, and they can be readily inactivated by platelet fac-
tor 4 or plasma proteins. In addition, they may lead
to heparin-induced thrombocytopenia (HIT II) with or
without thrombosis in a substantial number of patients
[3], and they are linked in long-term treatment with osteo-
porosis [4, 5], skin necrosis [6], hypersensitivity [7, 8], and
hypoaldosteronism [9]. These deficiencies and, in particu-
lar, the incidence of HIT II have recently led to an intense
search for suitable alternative anticoagulants [10]. Direct-
acting antithrombins, such as hirudin and its analogs have
several potential advantages over heparin [11, 12]. They
do not require a cofactor such as AT III, they are active
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against clot-bound thrombin [13, 14], and they have no
known natural inhibitors, such as platelet factor 4 [15].
Recombinant hirudin (r-hirudin) is evenly distributed
in the extracellular space and undergoes glomerular fil-
tration in unchanged form [16]. The elimination half-life
of r-hirudin ranges from about 0.8 to 1.6 hours in healthy
subjects, increases in impaired renal function [17, 18], and
is prolonged up to 50 times in patients with renal insuf-
ficiency [19, 20]. In cases of terminal renal impairment
(anuric patients, patients after bilateral nephrectomy) the
elimination halflife of r-hirudin was 80 to 120 hours [16,
20, 23]. PEG-Hirudin is a chemically defined conjugate
of an r-hirudin mutein and two molecules of polyethy-
lene glycol (PEG)-5000 with a mean molecular mass of
17 kD. It inhibits thrombin in a highly selective manner
and has a significantly longer duration of action compared
with non-conjugated r-hirudin [18, 21, 22]. After an intra-
venous bolus injection of 0.3 mg/kg body weight (BW)
in healthy subjects, its elimination half-life was about
8 times longer than that of r-hirudin [21]. In patients with
severe renal insufficiency but not undergoing hemodial-
ysis, its elimination half-life was further prolonged to
38.4 hours (26.0 to 87.2 hours) [18]. Because of its high
molecular mass PEG-Hirudin cannot be dialyzed by high-
or low-flux dialyzers [24]. The present study was primarily
designed to investigate the efficacy and safety of a PEG-
Hirudin dosage regimen for dialysis sessions consisting
of a single fixed bolus dose injection for the first session
and individually titrated single maintenance doses for the
subsequent sessions.
METHODS
Patients
Twenty patients (12 males and 8 females) with end-
stage renal disease (ESRD) who had been on mainte-
nance HD for 3.2 years (0.5 to 8 years) before study
initiation completed the study. One patient dropped out
due to severe thrombosis of the fistula during the heparin
treatment and had to be hospitalized. This patient was
withdrawn from the study and replaced. The patients had
a mean age of 57.8 years (37 to 71 years), a mean dry BW
of 71.4 kg (48.5 to 91.0 kg) and a mean body mass index
(BMI) of 25.3 kg/m2 (17.0–31.6 kg/m2). Renal failure was
caused by chronic glomerulonephritis (14 patients), dia-
betic nephropathy (3 patients), polycystic kidney disease
(2 patients), and other reasons (2 patients). Mean crea-
tinine clearance was 1.4 mL/min·1.73 m2 (ranging from
0 to 3.6 mL/min·1.73 m2). All patients had a perma-
nent native arteriovenous (AV) fistula. The study was
approved by the Ethics Committee of the Faculty of
Medicine at the University of Jena, Germany. Written
informed consent was obtained from each patient before
enrolment.
Study design and drug administration
The study was designed as a single-center, open-label,
dose-finding trial. At the first three dialysis sessions all
patients received their prestudy unfractionated heparin
(UFH) (Liquemin N 25 000, Roche, Germany) dose
regimen. This was followed by either 5 (group I) or 10
(group II) dialysis sessions using PEG-Hirudin as the
anticoagulant. The switch from UFH (bolus injection +
infusion) to PEG-Hirudin was blinded for the patients.
This was ensured by adding a placebo infusion to the
initial PEG-Hirudin bolus injection. PEG-Hirudin was
supplied by Knoll AG Ludwigshafen, Germany (now
Abbott GmbH and Company KG), in vials containing
20 mg PEG-Hirudin in lyophilisate form. The specific an-
tithrombin activity (ATU) was 13354 ATU/mg protein.
The anticoagulants were given in the arterial line of the
extracorporeal dialysis circuit.
The starting dose of PEG-Hirudin was a single bolus
injection of 80 lg/kg BW (HD4) for all patients except
for the first, who received 50 lg/kg BW, followed by a
12-lg/kg bolus about three hours later because of signif-
icant clotting in the dialysis system. The lower dose of
50 lg/kg was originally used because this dose proved to
be safe in patients with various degrees of renal insuffi-
ciency not undergoing hemodialysis [18] and resulted in
peak concentrations of about 1000 ng/mL, which were
considered sufficient for dialysis. For the following ses-
sions the single bolus PEG-Hirudin dose was individu-
ally adjusted and aimed at achieving a post-dialysis blood
concentration of at least 500 ng/mL and a peak blood
concentration of 950 ng/mL. Dose calculations for the
sessions were based on residual predialysis PEG-Hirudin
blood concentration values. These were obtained by de-
termining the ecarin clotting time (ECT) using calibra-
tion curves ranging from 0 to 1600 ng PEG-Hirudin/mL
blood. The mean PEG-Hirudin dose over all follow-up
sessions and patients (without the fixed initial dose) was
41 lg/kg BW (range 26 to 65 lg/kg BW). A detailed dos-
ing schedule is presented in Table 1.
Description of dialysis
The study encompassed a total of 213 dialysis sessions.
UFH was used as the anticoagulant in 63 of these ses-
sions, and PEG-Hirudin in 150. Each patient was hemodi-
alyzed three times a week for 3 to 5 hours (mean duration
4.3 hours) using a Gambro GFS plus 16 (Haemophan,
low-flux) dialyzer. Mean blood flow rate (QB) ranged
from 250 to 300 mL/min, and mean dialysate flow rate
(QD) was 500 mL/min. The mean ultrafiltration rate var-
ied between 505 and 663 mL/h (individual range 140 to
1000 mL/h).
The efficacy of dialysis was assessed by measuring urea
and creatinine serum levels, pressure on the venous side
of the dialyzer (PV), transmembrane pressure (TMP),
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Table 1. Mean UFH and PEG-Hirudin doses (range of individual doses)
Anticoagulant: UFH (HD1−3: N = 21)
Bolus dose injection + infusion dose according to the patients’ individual
pre-study dosage regimen
HD1: 49.30 (32.97–50.51) IU/kg + 9.20 (3.36–21.43) IU/kg/h
HD2: 50.11 (50.00–50.51) IU/kg + 9.36 (3.36–21.43) IU/kg/h
HD3: 50.11 (50.00–50.51) IU/kg + 9.36 (3.36–21.43) IU/kg/h
Anticoagulant: PEG-Hirudin (HD4−8: N = 20; HD9−13: N = 10) HD4: 80 lg/kg (1st patient: 50 + 12 lg/kg)
HD5: 55 (46–63) lg/kg
Fixed starting dose (HD4) followed by individually titrated PEG-Hirudin
doses (HD5−13). The doses were aimed at obtaining an ECT-derived
PEG-Hirudin blood concentration of at least 500 ng/mL measured
post-dialysis or a peak blood concentration of 950 ng/mL measured 5
minutes after bolus injection
HD6: 48 (38–62) lg/kg
HD7: 47 (37–65) lg/kg
HD8: 42 (27–51) lg/kg
HD9: 38 (32–46) lg/kg
HD10: 40 (32–47) lg/kg
HD11: 37 (26–48) lg/kg
HD12: 37 (30–48) lg/kg
HD13: 39 (32–48) lg/kg
Table 2. Score summary for clotting in dialyzer, air trap, and blood
line system
Number of dialysis sessions %
PH: 50 PH: 100
UFH: 60 (Grp I) (Grp II)
HD1−HD3 HD4−HD8 HD4−HD13
Scores for dialyzer clotting
1. clean dialyzer 39 (65.0) 44 (88.0) 64 (64.0)
2. few blood traces 15 (25.0) 4 (8.0) 32 (32.0)
(<5%)
3. many blood traces 2 (3.3) 2 (4.0) 4 (4.0)
(>5%)
4. coagulated dialyzer 4 (6.7) 0 0
Scores for air trap and blood line clotting
1. no clotting 29 (48.3) 31 (62.0) 69 (69.0)
2. presence of fibrinous 26 (43.3) 15 (30.0) 28 (28.0)
ring
3. clot formation 3 (5.0) 3 (6.0) 3 (3.0)
(up to 5 cm)
4. coagulated system 2 (3.3) 1 (2.0) 0
Abbreviations are: UFH, unfractionated heparin; PH, PEG-Hirudin; Grp,
group. Group I: 10 patients received UFH at 3 regular dialysis sessions (HD1−3)
followed by 5 dialysis sessions using PEG-Hirudin (HD4−8); group II: 10 patients
received UFH at 3 regular dialysis sessions (HD1−3) followed by 10 sessions on
PEG-Hirudin (HD4−13).
fiber bundle end volume (FBEV), and clot formation
in the dialyzer, air trap, and blood line. Clotting was
evaluated by visual inspection after blood draining and
documented according to the scores provided by the
Pharmacological Hemostaseology Research Unit, Uni-
versity of Jena (Table 2).
Monitoring of anticoagulation
Anticoagulation was monitored by measuring PEG-
Hirudin plasma and blood concentration values, acti-
vated partial thromboplastin time (aPTT), bleeding time,
platelet count, and AV fistula compression time. The
pharmacokinetic evaluation was based on the PEG-
Hirudin plasma concentration data.
To determine aPTT as well as PEG-Hirudin plasma
and blood concentrations derived from anti-IIa activ-
ity and ECT, respectively, 5 mL citrated blood was al-
ways collected pre- and post-dialysis and in addition in
HD1, HD4, HD8, and HD13 at 5, 30, 60, 120, and 180
minutes after start of dialysis. Predialysis blood was col-
lected 30 minutes before the application of the anticoag-
ulant. Post-dialysis blood was collected immediately after
the end of dialysis from the dialysis access site using cit-
rated monovettes (Sarstedt AG, Nu¨mbrecht, Germany).
For the determination of platelet count one aliquot of 40
lL citrated plasma was separated from the pre- and post
dialysis samples for anti-IIa activity, aPTT, and ECT and
analyzed on a CellDyn 1600 (Abbott GmbH and Com-
pany). Citrated blood was centrifuged at 3500 rpm for
10 minutes at room temperature within 20 minutes of
blood sampling. The supernatant plasma was separated
and aliquots were deep-frozen at −70◦C or colder in an
upright position until the assay was performed.
Actin FS (Dade International, Inc.) reagent was used
to determine aPTT. The samples were measured on an
ACL 3000 analyzer (Instrumentation Laboratory. Inc.).
Normal limits were defined as 23 to 33 seconds.
PEG-Hirudin concentrations in citrated plasma were
determined by measuring its anti-IIa activity by the
chromogenic substrate method (S-2238, Chromogenix,
Moelndal, Sweden) as described by Spannagl et al [25].
Anti-IIa activity is expressed as concentration (ng pro-
tein per mL citrated plasma) using PEG-Hirudin calibra-
tion curves ranging from 0 to 1600 ng PEG-Hirudin/mL
plasma. The limit of quantitation was set at 200 ng/mL.
PEG-Hirudin concentrations in citrated whole blood
were determined by ECT as described by Nowak and
Bucha [26] on a mechanical coagulometer (Thrombo-
track 8; Behnk Electronic, Norderstedt, Germany) us-
ing the following procedure: The ecarin reagent (50
EU/vial in lyophilisate form; Pentapharm, Ltd., Basel,
Switzerland) was dissolved in 5 mL of distilled water.
Citrated whole blood (100 lL) was incubated for 2 min-
utes at 37◦C. Ecarin reagent (100 lL) was added as a
starter and clotting time was measured in seconds. A cal-
ibration curve drawn up for each individual patient rang-
ing from 0 to 1600 ng/mL blood (determined in citrated
blood from a predialysis sample of each first session in-
cluded in the study) was used to derive the PEG-Hirudin
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concentrations from the clotting time measured. The
measurements were carried out in triplicate. The lower
limit of quantitation was set at 100 ng/mL.
Template bleeding time was measured by making a
standardized horizontal cut on the forearm with a Surgi-
cutt (International Technidyne Corp., Edison, NJ, USA)
device after inflating a sphygmomanometer cuff on the
upper arm to 40 mm Hg. Blood was absorbed from
the cut with filter paper after 30 seconds, and then at
30-second intervals until bleeding stopped, at which point
the time was recorded (normal range 4 to 10 minutes).
Bleeding time was measured within the screening period
and 2 hours after starting HD1 and HD8.
The compression time of the AV fistula after with-
drawal of the dialysis access needles was always measured
by the same medical investigator.
Safety assessments
Safety was assessed by evaluating adverse events, clin-
ical laboratory values, blood pressure measurements,
pulse rate, ECG, and body temperature. The following
hematologic parameters were determined: hemoglobin
(Hb), hematocrit (Hct), red blood cells (RBC), white
blood cells (WBC), and platelet count. Clinical chem-
istry included alanine aminotransferase (ALT), aspartate
aminotransferase (AST), gamma-glutamyl transferase
(c -GT), alkaline phosphatase, total bilirubin, cholesterol,
triglycerides, creatinine, urea, sodium (Na+), potassium
(K+), calcium (Ca++), C-reactive protein (CRP), total
protein, albumin, and carbohydrase deficient transfer-
rin (CDT). Total immunoglobulin E (IgE) antibod-
ies and titers of specific antibodies (IgM, IgG) against
PEG-Hirudin were determined by enzyme immunoassay
technique.
The test for hematuria was performed pre-study, be-
fore, and after HD4, HD8, and HD13 using reagent test
strips (Combur9-Test, Roche Diagnostics, Mannheim,
Germany). The feces were tested for occult blood with
hemoCARE (CARE Diagnostica, Mo¨llersdorf, Aus-
tria) during screening, before HD1, HD4, and HD13.
Biometric and statistic methods
All statistical analyses were performed using the Sta-
tistical Analysis System (SAS Institute, Inc., Cary, NC,
USA). The evaluation of pharmacokinetic parameters
was performed with compartment model dependent
methods using the program NonMem, Version V (Globo-
max LLC, Hanover, MD, USA). Concentrations below
limit of quantitation (LOQ) were not considered in the
calculation of pk parameters.
RESULTS
Efficacy of dialysis
Parameters describing the efficacy of dialysis produced
effective and comparable results during anticoagulation
using either UFH or PEG-Hirudin. The mean reduction
in urea was 66% (from 26.1 + 7.26 mmol/L to 8.8 +
3.02 mmol/L) at the end of HD1 (UFH) and 66% (from
25.6 + 5.91 mmol/L to 8.6 + 2.67 mmol/L), 67% (from
23.2 + 6.56 mmol/L to 7.6 + 2.55 mmol/L), and again
67% (23.3 + 5.04 mmol/L to 7.6 + 1.96 mmol/L) at the
end of the HD4, HD8, and HD13 PEG-Hirudin sessions,
respectively. The mean reduction in creatinine concen-
tration was 59% (from 975 + 150.2 lmol/L to 401 +
92.1 lmol/L) at the end of HD1 (UFH) and 60% (from
968 + 179.8 lmol/L to 392 + 118.9 lmol/L), 60% (from
905 + 181.7 lmol/L to 365 + 93.3 lmol/L), and 62% (from
925 + 89.5 lmol/L to 354 + 47.0 lmol/L) at the end
of HD4, HD8, and HD13 (PEG-Hirudin), respectively.
Mean pressure at the venous site of the dialyzer (PV)
ranged from 127.4 to 129.7 mm Hg (range of individ-
ual values 73 to 206 mm Hg) during anticoagulation with
UFH (HD1−3) and from 125.1 to 130.9 mm Hg (individ-
ual values 77 to 223 mm Hg) during anticoagulation with
PEG-Hirudin (HD4−13). Mean transmembrane pressure
(TMP) varied from 73.1 to 78.7 mm Hg (individual values
15 to 240 mm Hg) and from 55.6 to 81 mm Hg (individ-
ual values 15 to 166 mm Hg) during anticoagulation with
UFH and PEG-Hirudin, respectively. Mean FBEV mea-
sured after UFH sessions varied from 83.4 to 89.2 mL
(individual values 22 to 98 mL) and from 90.9 to 94.6 mL
(individual values 76 to 100 mL) after PEG-Hirudin ses-
sions. The fibers of the dialyzer presented either no clot-
ting or only minor clotting (grades 1–2) in 90% and 96%
of the UFH and PEG-Hirudin sessions, respectively
(Table 2). Clinically relevant clotting was observed in
10% of the UFH sessions (grades 3 and 4) and in 4%
of the PEG-Hirudin sessions (grade 3).
Air trap and blood line system presented either no clot-
ting or minimal clotting (grades 1–2) in 91.6% of the UFH
sessions, and in 92% (group I) and 97% (group II) of the
PEG-Hirudin sessions. Major clotting was found in 8.3%
of the UFH sessions, and in 8% (group I) and 3% (group
II) of the PEG-Hirudin sessions.
Activated thromboplastin time (aPTT)
In the UFH sessions HD1−3 mean predialysis aPTT lev-
els varied between 27.1 and 31.8 seconds. Five minutes af-
ter UFH bolus injection and starting the infusion in HD1,
mean aPTT was prolonged to 163.8 seconds (individual
range 82 to 250 seconds, corresponding to a 3.0- to 8.4-
fold prolongation over baseline). The mean post-dialysis
levels (HD1−3) were slightly prolonged and varied be-
tween 34.0 and 46.3 (see also Table 3 for mean values ±
SD of HD1, groups I + II, and Fig. 1).
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Table 3. Anticoagulant activity of unfractionated heparin (UFH) and PEG-Hirudin in hemodialysis
PEG-Hirudin PEG-Hirudin
plasma concentration blood concentration
APTT seconds ECT seconds ng/mL ng/mL
Group
No. HD No. Pre 5 min Post Pre 5 min Post Pre 5 min Post Pre 5 min Post
I HD1 31.5 139.1 46.1 50.7 53.0 46.6 N.A. N.A. N.A. N.A. N.A. N.A.
(7.0) (33.8) (34.6) (4.5) (4.1) (3.1)
II 28.0 188.4 36.3 49.1 53.0 44.7 N.A. N.A. N.A. N.A. N.A. N.A.
(2.2) (43.5) (12.5) (3.3) (4.7) (2.9)
I HD4 30.5 84.7 63.9 53.5 212.5 156.3 <LOQ 1194.6 848.1 <LOQ 915.8 567.2
(6.3) (21.1) (14.0) (5.5) (36.6) (18.7) (206.9) (63.4) (192.1) (102.3)
II 27.5 61.9 59.9 50.9 202.7 149.7 <LOQ 1297.5 818.0 <LOQ 920.7 575.0
(2.9) (17.7) (12.6) (5.6) (17.3) (16.3) (168.1) (84.7) (94.9) (53.3)
I HD8 55.9 71.7 66.6 123.9 210.2 175.5 487.7 1093.1 870.6 407.6 905.0 674.9
(11.6) (14.7) (11.9) (14.9) (26.2) (23.5) (94.3) (138.3) (76.0) (88.9) (116.2) (68.6)
II 54.2 71.5 68.1 118.4 205.2 170.5 536.0 1240.0 950.5 419.2 952.2 694.2
(10.3) (11.7) (20.1) (15.9) (23.7) (25.8) (74.9) (184.9) (215.4) (49.7) (84.4) (68.9)
II HD13 52.3 68.1 60.3 119.7 190.1 161.6 486.6 1075.6 834.2 470.2 939.7 710.3
(9.8) (8.7) (8.0) (12.8) (20.0) (18.7) (90.9) (186.3) (167.3) (77.9) (45.9) (40.4)
Anticoagulants are: UFH for HD1 and PEG-Hirudin for HD4+8+13. Data are expressed as mean values (± standard deviation). Pre, prior to hemodialysis, post, at
the end of hemodialysis, 5 min, time after bolus injection; N.A., not applicable; LOQ, limit of quantitation. PEG-Hirudin plasma and blood concentrations were derived
from anti-lla activity and ECT, respectively.
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Fig. 1. Mean (±2 SEM) effect-time course of activated partial throm-
boplastin time (aPTT) (seconds), Group II, N = 10 patients. S, start
of sessions [hemodialysis (HD1−13); E, end of sessions (HD1−13). An-
ticoagulants: unfractionated heparin (UFH) for HD1−3, PEG-Hirudin
for HD4−13. Blood sampling times for HD1+4+8+13: prior to HD, at 5
minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and post-dialysis. Blood
sampling times for HD2+3, HD5−7 and HD9−12: pre- and post-dialysis.
The intradialytic intervals (from S to E) represent a mean duration of
4.3 hours; the interdialytic intervals (from E to S) represent time periods
of 2 or 3 days.
In the PEG-Hirudin sessions mean predialysis aPTT
was prolonged from 29 seconds (HD4 = before the first
PEG-Hirudin bolus injection) to 48 seconds (HD5) and
then fluctuated between 52.2 and 56.1 seconds (HD6−13).
Five minutes after bolus injection of PEG-Hirudin mean
aPTT (range of individual values) was prolonged to
73.3 seconds (56 to 118 seconds), 71.6 seconds (53 to 103
seconds), and 68.1 seconds (59 to 90 seconds) in HD4,
HD8, and HD13, respectively. This corresponds to indi-
vidual aPTT ratios (value/baseline) of 1.8–4.2 (HD4), 1.4–
3.5 (HD8), and 2.2–2.7 (HD13). Mean post-dialysis aPTT
values fluctuated between 60 and 69 seconds, individual
values ranged from 44 to 119 seconds (see also Table 3
for mean values ± SD of HD4+8+13, group I + II, and
Fig. 1).
Bleeding time
Mean bleeding time was very similar after either anti-
coagulant. It was 6.57 minutes (range 1.5 to 16.5 minutes)
and 6.55 minutes (range 2.0 to 26.5 minutes) during an-
ticoagulation with UFH and PEG-Hirudin, respectively,
measured 2 hours after starting HD1 (UFH) and HD8
(PEG-Hirudin).
Platelet count
In general, a slight rise in platelet count was observed
at the end of the dialysis sessions compared to the pre-
dialysis value. Mean platelet count ranged from 236.9 to
240.6 × 109/L before and from 248.4 to 252.6 × 109/L at
the end of UFH sessions (HD1−3). For PEG-Hirudin the
values ranged from 218.6 to 240.7 × 109/L before, and
from 233.9 to 251.0 × 109/L at the end of HD4−13.
Compression time of AV fistula
After UFH sessions HD1−3 mean AV fistula com-
pression varied between 5.9 and 6.7 minutes, with in-
dividual values ranging from 2.0 to 27.4 minutes. After
PEG-Hirudin sessions HD4−8,10,12,13 mean compression
time varied between 6.7 and 8.0 minutes, but was
19.2 minutes and 17.0 minutes after HD9 and HD11,
respectively. This increase in mean compression time
was due to one patient with sustained aneurysm at the
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Table 4. Individual estimates for model parameters and derived pharmacokinetic parameters
Patient Weight Age Diuresis CLCR CL CL T 1/2
Group No. Gender kg years mL/24 h mL/min mL/min mL/min kg bH Vss l/kg
I 1 Male 91.0 49 0 0.0 1.54 0.017 97.4 0.13
I 2 Female 72.0 59 2000 3.6 2.19 0.030 66.2 0.15
I 4 Male 66.5 67 0 0.0 1.29 0.019 99.9 0.16
I 5 Male 81.5 64 800 1.8 1.64 0.020 87.4 0.14
I 6 Female 88.0 48 850 1.8 2.51 0.028 58.0 0.13
I 7 Female 63.5 71 0 0.0 1.34 0.021 106.5 0.18
I 8 Male 74.5 57 100 0.2 1.41 0.019 93.7 0.14
I 9 Female 64.0 61 0 0.0 1.37 0.021 102.9 0.18
I 10 Female 65.5 64 0 0.0 1.17 0.018 108.0 0.15
I 103 Male 51.0 58 1200 3.6 1.54 0.030 78.02 0.19
II 11 Male 72.5 58 595 1.2 1.32 0.018 98.1 0.15
II 12 Male 74.5 51 90 0.6 1.30 0.017 98.3 0.14
II 13 Male 75.0 61 800 3.6 1.57 0.021 81.2 0.14
II 14 Female 65.5 65 0 0.0 0.76 0.012 159.3 0.15
II 15 Male 81.0 45 0 0.0 1.09 0.014 114.3 0.13
II 16 Male 81.0 61 0 0.0 1.29 0.016 99.3 0.13
II 17 Male 62.5 37 900 3.0 1.18 0.019 116.7 0.18
II 18 Male 80.5 71 800 3.0 1.77 0.022 87.4 0.16
II 19 Female 48.5 44 1200 3.6 1.28 0.026 78.7 0.17
II 20 Female 68.5 64 300 1.8 1.52 0.022 109.7 0.20
Mean 71.4 58 481.8 1.4 1.45 0.021 97.1 0.15
STD 11.0 9.3 569.1 1.5 0.38 0.005 21.3 0.02
Min. 48.5 37 0 0.0 0.76 0.012 58.0 0.13
Max. 91.0 71 2000 3.6 2.51 0.030 159.3 0.20
Abbreviations are: CLCR, creatinine clearance; CL, total body clearance; Vss, apparent volume of distribution at steady state; T 1/2 b , terminal elimination half-life
calculated by model-dependent methods; STD, standard deviation.
vascular access site and compression times of 141 min-
utes (HD9) and 115 minutes (HD11). With the exception
of these two measurements, the individual compression
times ranged from 2.3 to 45 minutes (HD4−13). The me-
dian values for PEG-Hirudin ranged between 4.8 and
6.3 minutes (150 measurements), and were slightly pro-
longed in comparison to UFH (4.5 to 4.8 minutes; 63 mea-
surements).
PEG-Hirudin concentration and pharmacokinetics
Following PEG-Hirudin administration mean predial-
ysis PEG-Hirudin plasma concentrations increased to
536 ng/mL, measured before HD8 (Group II). There-
after (HD9−13), mean concentrations ranged from 462.4
to 517.8 ng/mL, without accumulation after the 5th PEG-
Hirudin injection. Mean PEG-Hirudin plasma levels
measured five minutes after bolus injection in HD4+8+13
fluctuated between 1075.6 and 1297.5 ng/mL, indicating
that the dose adjustments were well implemented. Mean
PEG-Hirudin concentrations measured at the end of dial-
ysis ranged from 818.0 to 995.1 ng/mL. Plasma levels
based on anti-IIa activity as well as PEG-Hirudin blood
concentration values based on ECT measurements are
presented in Table 3. PEG-Hirudin was eliminated with a
mean elimination half life of 97.1 h, with individual values
ranging from 58.8 to 159.3 h. Mean total body clearance
of PEG-Hirudin from the plasma was 1.45 mL/min (0.76
to 2.51 mL/min), which nearly corresponds to the mean
creatinine clearance of 1.4 mL/min · 1.73 m2 b.s. (0.0 to
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Fig. 2. Ecarin clotting time (ECT) (A) and activated partial throm-
boplastin time (aPTT) (B) versus PEG-Hirudin plasma concentration
relationship. The relationship between ECT and PEG-Hirudin, based
on anti IIa-activity, can be described with sufficient accuracy (r = 0.91),
whereas the relationship between aPTT and PEG-Hirudin is more vari-
able (r = 0.56).
3.6 mL/min). Individual and mean pharmacokinetic pa-
rameters are presented in Table 4. The relationship be-
tween the ECT and PEG-Hirudin concentration data can
be described on the basis of a linear regression with suf-
ficient accuracy (r = 0.91), whereas the relationship be-
tween aPTT and PEG-Hirudin concentrations is more
variable (r = 0.56), especially with higher PEG-Hirudin
concentration values (Fig. 2).
Safety assessments
As expected for this patient population, various ad-
verse events (AEs) were observed. Most frequently, mus-
cle cramp, hypotension, and headache were reported.
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Most of the AEs were mild and not related to the an-
ticoagulant therapy. There were no unexpected Aes, and
only one serious adverse event was reported in patient 3
(HD3), who received UFH (hospitalization and surgical
intervention due to thrombosis of the fistula). Hypoten-
sion and muscle cramps were also noted in this patient.
This patient was withdrawn from the study and replaced
by patient 103.
Microhematuria was seen in 11 of 14 patients with
residual renal function before enrollment in the study
and at the post-study examination. Macrohematuria was
not observed. The test for occult blood in the feces was
positive in one UFH-treated patient (HD1). No posi-
tive test results were found during anticoagulation with
PEG-Hirudin. WBC, RBC, Hb, and Hct did not rele-
vantly differ after either UFH or PEG-Hirudin. A slight
mean decline in RBC, Hb, and Hct compared to base-
line values might be attributable to repeated blood sam-
pling. The mean C-reactive protein concentrations were
8.67 mg/L and 8.68 mg/L, measured during the prestudy
examination and at HD13, respectively. Routine clinical
chemistry parameters as well as vital sign measurements
(blood pressure, pulse rate, body temperature) and ECG
tracings were not affected by either anticoagulant. Spe-
cific IgG or IgM anti-hirudin antibody titers (≥26) were
not found up to 6 weeks after the last dialysis session with
PEG-Hirudin.
DISCUSSION
Heparins are the anticoagulants of choice in long-term
hemodialysis treatment. But due to their shortcomings,
especially in terms of the increasing incidence of heparin-
induced thrombocytopenia type II (HIT II) in hemodial-
ysis patients [27–32], the search for alternatives has
recently been intensified. One alternative is r-hirudin, a
direct and highly specific thrombin inhibitor, which has al-
ready been used in HIT II patients undergoing hemodial-
ysis [19, 33–35]. Recently, more and more cases of HIT
II have been identified in hemodialysis patients [28, 36,
37]. The first two successful hemodialysis sessions using
r-hirudin as an anticoagulant were reported in 1989 by
Thieler et al [38]. Further studies investigating r-hirudin
for single hemodialysis were reported by Vanholder et
al and van Wyk et al [39, 40]. Bucha et al studied 10
hemodialysis patients on r-hirudin (CLCR 0 to 13 mL/
min · 1.73 m2) [10]. The authors concluded that r-hirudin
might be an efficient and safe alternative to heparin in
hemodialysis if residual renal function is considered for
dosage and dose adjustment, and ecarin clotting time is
available for drug monitoring [10]. However, as noncon-
jugated r-hirudin can be dialyzed, its reliable use is also
restricted to certain membranes, and effective plasma lev-
els during dialysis might sometimes be difficult to achieve
[19, 41]. Recently, two case reports of serious bleeding
incidence in hemodialysis patients point to the fact that
r-hirudin anticoagulation should be carefully monitored
[28, 42].
High-flux dialyzers are permeable to r-hirudin. In cases
of overdosage they can be used to eliminate r-hirudin. The
experimental data indicates that meizothrombin might
serve as an antidote; however, this has not been prop-
erly evaluated [24]. The use of r-hirudin has so far been
restricted to patients with heparin-induced thrombocy-
topenia.
To prolong the elimination half-life, hirudin has been
coupled to two molecules of polyethylene glycol-5000
(PEG), resulting in a specially designed recombinant
mutant of hirudin. This chemically stable compound
(PEG-Hirudin) has a mean molecular mass of 17 kD and
exhibits high specific activity and selectivity for throm-
bin. The compound is predominantly excreted by the
kidney. After intravenous bolus injection of 0.3 mg/kg
in healthy volunteers, the median elimination half-life of
PEG-Hirudin was 12 hours [21] compared to rhirudin
with 1.4 hours [16]. As a result, the antithrombotic effi-
cacy of PEG-Hirudin is two- to six-fold higher than that
of r-hirudin in various animal models [43, 44]. However,
the differences in the pharmacokinetic properties of the
two hirudins are of particular importance in individuals
with normal or residual renal function. In patients with
severely impaired renal function, the mean half-lives of
r-hirudin and PEG-Hirudin are both prolonged to about
100 hours.
Using virtually all commercially available high- and
low-flux membranes (except polymer membranes of the
acrylate type like polymethyl methacrylate, which binds
PEG-Hirudin), PEG-Hirudin offers the advantage over
non-conjugated r-hirudin of providing efficient antico-
agulation during dialysis while not being dialyzed itself
[24]. This ensures a stable and predictable blood concen-
tration during dialysis with a single injection of PEG-
Hirudin. This quality of not being dialyzed, together with
its unique pharmacokinetic behavior, provides not only
efficient anticoagulation during dialysis at a low dose of
PEG-Hirudin, but also results in a residual PEG-Hirudin
blood concentration in the interval between dialysis ses-
sions that might have the potential of reducing the in-
cidence of cardiac and other vascular events, including
access complications in patients with ESRD. Even if there
were no signs of bleeding in this study, residual PEG-
Hirudin may potentially be associated with a bleeding
risk. Further studies would need to confirm this safety
aspect of the proposed drug regimen. In cases of ac-
cidental overdosage or bleeding complications, PEG-
Hirudin can be eliminated with polymer membranes
of the acrylate type like polymethyl methacrylate [24].
Reduced antigenicity and immunogenicity can be ex-
pected from the polyethylene glycol (PEG) binding to an
r-hirudin mutein, resulting in PEG-Hirudin [45]. From a
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pharmacokinetic point of view, PEG-Hirudin has the ad-
vantage that equilibration between the blood compart-
ment and the extracellular water compartment is much
slower than with r-hirudin [16, 18]. Therefore, it can be
concluded that distinctly smaller maintenance doses are
required for effective dialysis with PEG-Hirudin com-
pared to r-hirudin.
In a previous study in patients with various degrees of
renal impairment not requiring HD [18], a bolus injec-
tion of 50 lg/kg PEG-Hirudin, resulting in peak plasma
concentrations of about 1000 ng/mL independently of
the degree of renal impairment, proved to be safe and
was considered to be the appropriate initial dose in our
patients with ESRD undergoing maintenance HD. How-
ever, about 3 hours after injecting this PEG-Hirudin dose
in the first patient, relevant clotting in the dialysis sys-
tem was observed and an additional PEG-Hirudin bo-
lus dose injection (12 lg/kg) had to be given. Therefore,
the starting dose of PEG-Hirudin for the subsequent pa-
tients was increased to 80 lg/kg. This fixed single bo-
lus dose injection provided efficacious anticoagulation
for each of the subsequent initial dose dialysis sessions
(HD4). At the end of the interdialytic intervals patients al-
ways presented with residual PEG-Hirudin levels, which
were used as the basis for dose titration. Residual lev-
els increased (HD5−8), but a fairly constant blood con-
centration was already reached from the sixth dialysis
session with PEG-Hirudin (HD9) onward. At HD9, PEG-
Hirudin doses ranged from 32 to 46 lg/kg (mean 38 lg/
kg). These individually titrated doses were nearly identi-
cal to the doses given at HD13, which ranged from 32 to
48 lg/kg (mean 39 lg/kg). This supports the concept of
a PEG-Hirudin dosage regimen with fixed maintenance
doses during prolonged PEG-Hirudin treatment. Dose
titration aimed at obtaining (ECT-derived) blood con-
centrations of at least 500 ng/mL measured at the end of
dialysis or a peak concentration of 950 ng/mL measured
5 minutes after bolus injection. These levels were pre-
dominantly reached and proved to be efficacious enough
to prevent clotting and safe enough to avoid bleeding with
PEG-Hirudin anticoagulation.
PEG-Hirudin can be easily and reliably monitored by
ECT, a precise assay with bedside quality [26]. There is a
close linear relationship between ECT and PEG-Hirudin
concentrations (r = 0.91) in contrast to aPTT versus PEG-
Hirudin (r = 0.56) and, in addition, ECT has the advan-
tage of being insensitive to heparin, allowing for specific
measurement of PEG-Hirudin in the blood, even in the
presence of UFH. No relevant safety problems were en-
countered after either of the anticoagulants, and PEG-
Hirudin was well tolerated in ESRD patients. Clotting in
the air trap and dialyzer was evaluated according to a rat-
ing scale. The PEG-Hirudin results were better than those
for UFH. Similarly, the FBEV of the dialyzer seemed
to be higher under PEG-Hirudin therapy. Compression
time at the vascular access site was slightly prolonged
after PEG-Hirudin treatment, which is likely be an indi-
cation of its prolonged anticoagulant effect compared to
UFH.
CONCLUSION
This study confirmed the usefulness and tolerability of
a PEG-Hirudin dose regimen consisting of a single fixed
80 lg/kg BW bolus injected before starting the first dial-
ysis session (HD4), followed by a dose titration period
over at least 4 sessions (HD5−8), which again was fol-
lowed by a fixed maintenance dose period (HD9−13). On
the basis of PEG-Hirudin data from patients with various
degrees of renal insufficiency but not undergoing
hemodialysis and prior r-hirudin experience, patients
were titrated into an ECT-controlled mean dose range
of 41 lg/kg BW (range 26 to 65 lg/kg BW; HD8−13),
which proved to be efficacious enough to prevent clot-
ting and safe enough to prevent bleeding. Owing to
its quality of not being dialyzed by the commercially
available membranes and its favorable pharmacokinetic
properties, PEG-Hirudin maintains residual blood con-
centrations in the intervals between dialysis sessions that
might have the potential of reducing the incidence of car-
diac and other vascular events, including access compli-
cations in patients with ESRD.
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